Drug Profile

EGL 003

Alternative Names: EGL-003

Latest Information Update: 08 Apr 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Egle Therapeutics
Class Antineoplastics; Immunoglobulin Fc fragments; Immunotherapies; Interleukins; Recombinant fusion proteins
Mechanism of Action Interleukin 2 inhibitors; Regulatory T-lymphocyte modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Autoimmune disorders; Cancer

Most Recent Events

17 Mar 2025 Egle Therapeutics expects to file a CTA for EGL 003 for Autoimmune disorders
17 Mar 2025 Egle Therapeutics plans a clinical trial of EGL 003 in Autoimmune disorders (Parenteral), in 2025
17 Jul 2024 Pharmacodynamics data from a preclinical study in Autoimmune disorders released by Egle Therapeutics

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com